期刊文献+

转录因子Sp1在心血管疾病中的作用 被引量:3

The role of transcription factor Sp1 on cardiovascular diseases
原文传递
导出
摘要 特异性蛋白1(specificity protein 1, Sp1)是Sp/KLF转录因子家族中最先被发现的一个转录因子。Sp1通过与靶基因启动子上特定的识别位点相结合,从而调控基因的表达,发挥调节细胞生理功能的作用。同时,Sp1的表达和功能也受到乙酰化、磷酸化、泛素化等翻译后修饰的影响。Sp1参与调节心肌细胞凋亡、心肌肥大、心肌纤维化、心肌细胞炎性反应、氧化应激和血管内皮细胞损伤、脂质沉积等多种病理过程,进而影响冠心病、心肌病和动脉粥样硬化等疾病的发生发展。本文将对Sp1在心血管疾病中的研究进展作一综述,以期为心血管疾病的防治提供新视野。 As a transcription factor,specificity protein 1(Sp1)was the first one to be discovered in the Sp/KLF transcription factors family.Sp1 regulates gene expression by binding to specific recognition sites on target gene promoters,and plays a role in regulating cell biological functions,meanwhile,the expression and function of Sp1 are also affected by post-translation modifications such as acetylation,phosphorylation and ubiquitination.In recent years,it has been found that Sp1 is involved in the regulation of myocardial apoptosis,myocardial hypertrophy,myocardial fibrosis,myocardial inflammatory response,oxidative stress,vascular endothelial cell injury,lipid deposition and other pathological processes,and thereby affecting the occurrence and development of coronary heart disease,cardiomyopathy,atherosclerosis and so on.This article will review the research progress of Sp1 in cardiovascular diseases in order to provide a new vision for the prevention and treatment of cardiovascular diseases.
作者 郑涛 杨俊 杨简 刘晓雯 李奇 ZHENG Tao;YANG Jun;YANG Jian;LIU Xiaowen;LI Qi(Department of Cardiology,First College of Clinical Medical Sciences,Institute of Cardiovascular Diseases,China Three Gorges University,Yichang 443003,China)
出处 《生命的化学》 CAS CSCD 2019年第3期478-484,共7页 Chemistry of Life
基金 国家自然科学基金项目(81170133,81670333) 湖北省科技支撑计划项目(2015BKA340)
关键词 SP1 心血管疾病 凋亡 心肌纤维化 钙化 Sp1 cardiovascular disease apoptosis myocardial fibrosis calcification
  • 相关文献

参考文献2

二级参考文献27

  • 1Opie L H, Commerford P J, Gersh B J, et al. Controversies in ventricular remodelling. Lancet, 2006, 367: 356-367.
  • 2Biswas A, Rabbani S I, Devi K. Influence of pioglitazone on experimental heart failure and hyperlipidemia in rats. Indian J Pharmacol, 2012,44: 333-339.
  • 3Kataoka Y, Yagi N, Kokubu N, et al. Effect of pretreatment with pioglitazone on reperfusion injury in diabetic patients with acute myocardial infarction. Circ J, 2011, 75: 1968-1974.
  • 4Shiomi T, Tsutsui H, Hayashidani S, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation, 2002,106: 3126-3132.
  • 5Wayman N S, Hattori Y, Mcdonald M C, et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPARalpha) reduce myocardial infarct size. FASEB J, 2002, 16: 1027-1040.
  • 6Yasuda S, Kobayashi H, Iwasa M, et al. Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction. Am J Physiol Heart Circ Physiol, 2009, 296: H1558-H 1565.
  • 7Mohite A J, Chillar A J, Wijaya C, et al. Endogenous prostacyclin signaling regulating microRNA expression in mammalian cells. FASEB J, 2009, 23: LB373.
  • 8van Rooij E, Sutherland L B, Thatcher J E, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA, 2008, lOS: 13027-13032.
  • 9Cheng K, Malliaras K, Shen D, et al. Intramyocardial injection of platelet gel promotes endogenous repair and augments cardiac function in rats with myocardial infarction. J Am Coli Cardiol, 2012, 59: 256-264.
  • 10Simpson P, Savion S. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Crossstriations, ultrastructure, and chronotropic response to isoproterenol. Circ Res, 1982, 50: 10 1-116.

共引文献15

同被引文献57

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部